Tim Whitten, Taiho Oncology CEO
October 3, 2022 07:21 AM EDT
R&D
FDA+

FDA green­lights Ot­su­ka sub­sidiary's bile duct can­cer drug

Zachary Brennan

Senior Editor

Ot­su­ka sub­sidiary Tai­ho On­col­o­gy nabbed an ac­cel­er­at­ed ap­proval on Fri­day for Lyt­go­bi (futiba­tinib), its new ki­nase in­hibitor to treat adults with a type of pre­vi­ous­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

FDA OKs the first-ever self-ad­min­is­tered vac­cine, for flu

The drug lob­by's law­suit against the IRA finds a sign of life af­ter ap­peals court rul­ing

Biotech VC firm out­lines plans for $100M fund

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times